【招商证券：海西新药(02637.HK)HX9428有望填补口服治疗nAMD蓝海】智通财经APP获悉，招商证券发布研报称，海西新药(02637.HK)口服眼底病创新药HX9428有望解决临床治疗痛点，潜在市场空间广阔，首次覆盖给予"增持"评级。该行预计公司2026-2028年实现归母净利润1.79/2.07/2.39亿元，对应增速1%/16%/16%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.